Company intelligence / Profile preview

EyeMacular Regeneration, Inc.

Rochester, Minnesota, USAlinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

EyeMacular Regeneration, Inc. and its predecessor iMacular Regeneration, LLC are developing novel therapies and intraocular drug delivery technologies targeting end-stage age-related macular degeneration and other retinal diseases. Their work includes translational research based on the Minnesota Grading System for AMD and has been supported by over $8.7 million in NIH/NEI-STTR-SBIR grants under the leadership of Dr. Timothy W. Olsen.

Therapeutic areas: Ophthalmology
Modalities: Intraocular drug delivery systemsNovel therapies for end-stage macular diseaseTranslational research in age-related macular degeneration (AMD)
Industry: Biotech

Beyond the preview

Go deeper on EyeMacular Regeneration, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeMacular Regeneration, Inc..

Explore the full profile